IRVINE, Calif., & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News: MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, and PLUS Diagnostics today announced that they have entered into an agreement to co-promote MDxHealth’s ConfirmMDx™ for Prostate Cancer test in the United States.
